In the ATN framework, the biological state of AD is classified through the identification of three biomarkers (i.e., amyloid, tau, and neurodegeneration) measured from cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging [4]. This evidence concerns the gene MAPT and Alzheimer disease.